ACELYRIN Announces Pricing of Upsized Initial Public Offering
May 15, 2023
Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.
Cooley advised AiFi on its $65 million Series B funding round. Partner Gordon Ho led the Cooley team advising AiFi, which is a flexible artificial intelligence platform that enables retailers to affordably deploy and scale autonomous shopping solutions.
Cooley advised Diamond Age on its $50 million Series A funding round. Partner Gordon Ho led the Cooley team advising Diamond Age, which is a full-stack robotics startup that is automating new home construction to make homeownership more affordable.